BIO TISSUE

AmnioGraft® and AmnioGuard™ are listed with the FDA as a HCT/P (Human Cell, Tissue, and Cellular and Tissue-Based Product).
more >

PROKERA® is listed with the FDA as a Class II medical device. more >

Contact Us

Prominent Doctors Speak on Biological Advances in Treating Ocular Surface Inflammation

MIAMI, Fla., June 12, 2013 – Bio-Tissue, Inc., an ophthalmic biological therapeutics company, recently sponsored a lecture on "Biological Advances in Treating Ocular Surface Inflammation” presented by Christopher J. Rapuano, MD and Neel R. Desai, MD, during this year’s American Society of Cataract and Refractive Surgery (ASCRS) in San Francisco. 

The lecture focused on corneal inflammation and healing and in particular how inflammation is often the hallmark sign of ocular surface diseases and needs to be controlled in order to promote healing and prevent damage.  The session also addressed: 

- The treatment of conjunctival inflammatory diseases such as pterygium surgery, conjunctivochalasis (CCH), and surface squamous neoplasia. 

- The benefits of using an amniotic membrane graft for ocular surface wound repair and healing including its anti-inflammatory, anti-scarring, and anti-angiogenic actions. 

- The benefits of Bio-Tissue’s PROKERA®, the only FDA cleared therapeutic device that reduces inflammation and promotes healing; and its AmnioGraft®, a Biologic Ocular Transplantation Graft.

“Reducing inflammation and promoting healing is crucial to the successful management of ocular surface disease,” said Christopher J. Rapuano, MD. “Current treatment options can be frustrating for both doctor and patients as they may not reduce inflammation enough and do not promote healing. Bio-Tissue’s PROKERA® offers a dual-action solution for optimal patient outcomes.”